Clinical observation on sindilizumab combined with lenvastinib in the treatment of advanced liver cancer
Objective To investigate the clinical effect of sindilizumab combined with lenvatinib in the treatment of advanced liver cancer.Methods The 42 patients with advanced liver cancer in the Nanfeng County People's Hospital from January 2019 to January 2023 were selected as the study objects and divided into two groups according to the time of admission and treatment.The 21 patients in the control group was given with oral renvastinib,and 21 patients in the obser-vation group was given with oral renvastinib and intravenous sinillizumab.The short-term efficacy,survival,liver function indexes,tumor markers and adverse reactions of the two groups were compared.Results The disease control rate in the observation group was 85.7%,which was higher than that in the control group(57.1%)(χ2=4.200,P=0.040).The overall survival and progression-free survival in the observation group were longer than those in the control group(t=12.654,P<0.001;t=14.324,P<0.001).After treatment,the levels of serum aspartate transaminase,total bilirubin,alanine aminotransferase in the observation group were lower than those in the control group(t=5.645,P<0.001;t=7.012,P<0.001;t=6.654,P<0.001).After treatment,the levels of serum carbohydrate antigen 199,carcinoembry-onic antigen,alpha fetoprotein in the observation group were lower than those in the control group(t=7.689,P<0.001;t=7.342,P<0.001;t=15.698,P<0.001).There was no significant difference in the total incidence of adverse reac-tions between the two groups(χ2=2.043,P=0.153).Conclusion Sindilizumab combined with lenvatinib in the treat-ment of advanced liver cancer has good clinical effect and high safety,providing a new treatment method for patients who cannot be operated in the advanced stage.
NETL
NSTL
万方数据
